Versigent (VGNT) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Based on 8 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Argus Research | Maintained | Buy | $54.00 from $50.00 | Aug 13, 2026 |
| Evercore ISI Group | Maintained | Outperform | $65.00 from $60.00 | Aug 10, 2026 |
| Wells Fargo | Maintained | Overweight | $56.00 from $48.00 | Aug 5, 2026 |
| RBC Capital | Upgraded | Sector Perform → Outperform | $52.00 from $41.00 | Aug 5, 2026 |
| TD Cowen | Maintained | Buy | $58.00 from $49.00 | Aug 5, 2026 |
| Goldman Sachs | Initiated Coverage | Buy | $48.00 | Jul 20, 2026 |
| RBC Capital | Maintained | Sector Perform | $41.00 from $34.00 | Jul 13, 2026 |
| UBS | Maintained | Buy | $55.00 from $58.00 | Jul 9, 2026 |
| Deutsche Bank | Upgraded | Hold → Buy | $50.00 | Jul 8, 2026 |
| Wells Fargo | Maintained | Overweight | $48.00 from $42.00 | Jun 25, 2026 |
| UBS | Maintained | Buy | $58.00 from $49.00 | Jun 5, 2026 |
| Wells Fargo | Maintained | Overweight | $42.00 from $35.00 | May 6, 2026 |
| TD Cowen | Maintained | Buy | $49.00 from $47.00 | May 6, 2026 |
| UBS | Maintained | Buy | $49.00 from $43.00 | May 6, 2026 |
| Deutsche Bank | Initiated Coverage | Hold | $35.00 | Apr 28, 2026 |
| UBS | Initiated Coverage | Buy | $43.00 | Apr 14, 2026 |
| Wells Fargo | Initiated Coverage | Overweight | $35.00 | Apr 6, 2026 |
Frequently asked questions
What is the price target for VGNT stock?
The average 12-month analyst price target for Versigent (VGNT) is $54.75, with a high estimate of $65.00 and a low of $48.00, across 8 analysts.
Is VGNT a buy, sell, or hold?
Analysts covering Versigent currently average a Buy rating: 11 buy, 1 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for VGNT?
The average price target of $54.75 implies 14.28% upside from the last price of $47.91.
What is the latest analyst rating on VGNT?
On Aug 13, 2026, Argus Research maintained Versigent at Buy with a price target of $54.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.